The Nordic Society of Paediatric Haematology and Oncology (NOPHO), established in 1984, has been a successful and productive society leading to improved survival rates of childhood leukemias, Acute Lymphoblastic Leukemia (ALL) and Acute Myeloblastic Leukemia (AML).
A unique multi-country database network with data from healthcare registers in Denmark, Norway, Sweden and Scotland with the purpose of conducting epidemiological studies on Covid-19.
Acute myelogenous leukemia (AML) is the most coomon acute leukemia in adults with and annual incidence of 4 cases per 100 000 inhabitans. Median age at diagnosis is 70 years. For patients below 55 years, the prognosis has gradually improved the last decades, but elderly patiens still do poorly; the survival being around 30% with no improvement of outome after standard chemotherapy treatment.
